<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="announcement"><front><journal-meta><journal-id journal-id-type="nlm-ta">Jpn J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Jpn. J. Clin. Oncol</journal-id><journal-id journal-id-type="publisher-id">jjco</journal-id><journal-id journal-id-type="hwp">jjco</journal-id><journal-title-group><journal-title>Japanese Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0368-2811</issn><issn pub-type="epub">1465-3621</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27655905</article-id><article-id pub-id-type="pmc">5421580</article-id><article-id pub-id-type="doi">10.1093/jjco/hyw140</article-id><article-id pub-id-type="publisher-id">hyw140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trial Note</subject></subj-group></article-categories><title-group><article-title>A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ohue</surname><given-names>Masayuki</given-names></name><xref ref-type="aff" rid="hyw140af1">1</xref><xref ref-type="corresp" rid="hyw140cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Iwasa</surname><given-names>Satoru</given-names></name><xref ref-type="aff" rid="hyw140af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kanemitsu</surname><given-names>Yukihide</given-names></name><xref ref-type="aff" rid="hyw140af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hamaguchi</surname><given-names>Tetsuya</given-names></name><xref ref-type="aff" rid="hyw140af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shiozawa</surname><given-names>Manabu</given-names></name><xref ref-type="aff" rid="hyw140af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>Masaaki</given-names></name><xref ref-type="aff" rid="hyw140af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yasui</surname><given-names>Masayoshi</given-names></name><xref ref-type="aff" rid="hyw140af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Katayama</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="hyw140af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Mizusawa</surname><given-names>Junki</given-names></name><xref ref-type="aff" rid="hyw140af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Shimada</surname><given-names>Yasuhiro</given-names></name><xref ref-type="aff" rid="hyw140af7">7</xref></contrib><on-behalf-of>on behalf of the Colorectal Cancer Study Group/Japan Clinical Oncology Group</on-behalf-of><aff id="hyw140af1"><label>1</label><addr-line>Department of Surgery</addr-line>, <addr-line>Osaka Medical Center for Cancer and Cardiovascular Diseases</addr-line>, <addr-line>Osaka</addr-line></aff><aff id="hyw140af2"><label>2</label><addr-line>Gastrointestinal Medical Oncology Division</addr-line>, <addr-line>National Cancer Center Hospital</addr-line>, <addr-line>Tokyo</addr-line></aff><aff id="hyw140af3"><label>3</label><addr-line>Colorectal Surgery Division</addr-line>, <addr-line>National Cancer Center Hospital</addr-line>, <addr-line>Tokyo</addr-line></aff><aff id="hyw140af4"><label>4</label><addr-line>Department of Gastrointestinal Surgery</addr-line>, <addr-line>Kanagawa Cancer Center</addr-line>, <addr-line>Yokohama</addr-line></aff><aff id="hyw140af5"><label>5</label><addr-line>Department of Colorectal Surgery</addr-line>, <addr-line>National Cancer Center Hospital East</addr-line>, <addr-line>Chiba</addr-line></aff><aff id="hyw140af6"><label>6</label><addr-line>JCOG Data Center/Operations Ofﬁce</addr-line>, <addr-line>National Cancer Center</addr-line>, <addr-line>Tokyo</addr-line></aff><aff id="hyw140af7"><label>7</label><addr-line>Clinical Oncology Division</addr-line>, <addr-line>Kochi Health Sciences Center</addr-line>, <addr-line>Kochi</addr-line>, <country>Japan</country></aff></contrib-group><author-notes><corresp id="hyw140cor1"><label>*</label>For reprints and all correspondence: Masayuki Ohue, Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan. E-mail: <email>ohue-ma@mc.pref.osaka.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>24</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>1</month><year>2017</year></pub-date><volume>47</volume><issue>1</issue><fpage>84</fpage><lpage>87</lpage><history><date date-type="received"><day>19</day><month>5</month><year>2016</year></date><date date-type="rev-recd"><day>31</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>© The Author 2016. Published by Oxford University Press.</copyright-statement><copyright-year>2016</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p></license></permissions><self-uri content-type="pdf" xlink:href="hyw140.pdf"></self-uri><abstract abstract-type="precis"><p><offsets xml_i="6206" xml_f="6408" txt_i="11" txt_f="213">This is a randomized controlled trial to confirm the superiority of perioperative mFOLFOX6 to postoperative mFOLFOX6 in the treatment of lower rectal cancer with suspected lateral lymph node metastasis.</offsets></p></abstract><abstract><p><offsets xml_i="6436" xml_f="7601" txt_i="225" txt_f="1390">A randomized phase II/III trial was started in May 2015 comparing perioperative versus postoperative chemotherapy with modified infusional ﬂuorouracil and folinic acid with oxaliplatin for lower rectal cancer patients with suspected lateral pelvic node metastasis. The standard arm is total mesorectal excision or tumor-specific mesorectal excision with lateral pelvic node dissection (LND) followed by postoperative chemotherapy (modified infusional ﬂuorouracil and folinic acid with oxaliplatin; 12 cycles). The experimental (perioperative chemotherapy) arm is six courses of modified infusional ﬂuorouracil and folinic acid with oxaliplatin before and six courses after total mesorectal excision with lateral pelvic node dissection. The aim of this trial is to confirm the superiority of perioperative chemotherapy. A total of 330 patients will be enrolled over 7 years. The primary endpoint in Phase II part is proportion of R0 resection and that in Phase III part is overall survival. Secondary endpoints are progression-free survival, local progression-free survival, etc. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000017603 [</offsets><uri xlink:href="http://www.umin.ac.jp/ctr/index-j.htm"><offsets xml_i="7657" xml_f="7694" txt_i="1390" txt_f="1427">http://www.umin.ac.jp/ctr/index-j.htm</offsets></uri><offsets xml_i="7700" xml_f="7702" txt_i="1427" txt_f="1429">].</offsets></p></abstract><kwd-group><kwd>randomized controlled trial</kwd><kwd>lower rectal cancer</kwd><kwd>lateral pelvic node metastasis</kwd><kwd>lateral pelvic node dissection</kwd><kwd>mFOLFOX6</kwd></kwd-group><counts><page-count count="4"></page-count></counts></article-meta></front><body><sec id="hyw140s1"><title><offsets xml_i="8016" xml_f="8041" txt_i="1437" txt_f="1462">Backgrounds and rationale</offsets></title><p><offsets xml_i="8052" xml_f="8136" txt_i="1463" txt_f="1547">Colorectal cancer is one of the main leading causes of death from cancer worldwide (</offsets><xref rid="hyw140C1" ref-type="bibr"><offsets xml_i="8173" xml_f="8174" txt_i="1547" txt_f="1548">1</offsets></xref><offsets xml_i="8181" xml_f="8538" txt_i="1548" txt_f="1905">). The prevention, early diagnosis and development of improved treatments for colorectal cancer are very urgent tasks. In the treatment of locally advanced lower rectal cancer, preoperative chemoradiation (CRT) followed by total mesorectal excision or tumor-specific mesorectal excision (TME) is the standard surgical procedure in Europe and North America (</offsets><xref rid="hyw140C2" ref-type="bibr"><offsets xml_i="8575" xml_f="8576" txt_i="1905" txt_f="1906">2</offsets></xref><offsets xml_i="8583" xml_f="8678" txt_i="1906" txt_f="2001">). In Japan, however, TME with lateral pelvic node dissection (LND) is the standard procedure (</offsets><xref rid="hyw140C3" ref-type="bibr"><offsets xml_i="8715" xml_f="8716" txt_i="2001" txt_f="2002">3</offsets></xref><offsets xml_i="8723" xml_f="8806" txt_i="2002" txt_f="2085">), with a similar incidence of local recurrence to the treatment with CRT and TME (</offsets><xref rid="hyw140C4" ref-type="bibr"><offsets xml_i="8843" xml_f="8844" txt_i="2085" txt_f="2086">4</offsets></xref><offsets xml_i="8851" xml_f="9114" txt_i="2086" txt_f="2349">). The Japan Clinical Oncology Group (JCOG) has conducted a randomized controlled trial (JCOG0212) to confirm the non-inferiority of the TME over the TME with LND for clinical stage II or stage III patients without suspected lateral pelvic node metastasis (LNM) (</offsets><xref rid="hyw140C5" ref-type="bibr"><offsets xml_i="9151" xml_f="9152" txt_i="2349" txt_f="2350">5</offsets></xref><offsets xml_i="9159" xml_f="9344" txt_i="2350" txt_f="2535">). However, patients with lower rectal cancer with LNM are considered to be a high-risk group and have a worse prognosis than those without LNM, with a 5-year overall survival of ~40% (</offsets><xref rid="hyw140C6" ref-type="bibr"><offsets xml_i="9381" xml_f="9382" txt_i="2535" txt_f="2536">6</offsets></xref><offsets xml_i="9389" xml_f="9513" txt_i="2536" txt_f="2660">). TME with LND should be strongly considered for R0 resection when the tumor invades beyond the extent of TME (beyond TME).</offsets></p><p><offsets xml_i="9520" xml_f="9693" txt_i="2661" txt_f="2834">With regard to adjuvant treatment, several recent papers have reported that additional CRT with TME does not improve survival and is not efficient for the treatment of LNM (</offsets><xref rid="hyw140C7" ref-type="bibr"><offsets xml_i="9730" xml_f="9734" txt_i="2834" txt_f="2838">7, 8</offsets></xref><offsets xml_i="9741" xml_f="9891" txt_i="2838" txt_f="2988">). However, postoperative adjuvant chemotherapy with 5-fluorouracil has been shown to improve the survival of patients with resectable rectal cancer (</offsets><xref rid="hyw140C9" ref-type="bibr"><offsets xml_i="9928" xml_f="9929" txt_i="2988" txt_f="2989">9</offsets></xref><offsets xml_i="9936" xml_f="9937" txt_i="2989" txt_f="2990">,</offsets><xref rid="hyw140C10" ref-type="bibr"><offsets xml_i="9975" xml_f="9977" txt_i="2990" txt_f="2992">10</offsets></xref><offsets xml_i="9984" xml_f="10168" txt_i="2992" txt_f="3176">). In addition, a more intensive adjuvant treatment with oxaliplatin, fluorouracil and leucovorin (FOLFOX) improved the overall survival of patients with stage II or III colon cancer (</offsets><xref rid="hyw140C11" ref-type="bibr"><offsets xml_i="10206" xml_f="10208" txt_i="3176" txt_f="3178">11</offsets></xref><offsets xml_i="10215" xml_f="10425" txt_i="3178" txt_f="3388">). Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 recommended 5-FU + leucovorin, UFT + leucovorin, Cape, FOLFOX and CapeOX as adjuvant chemotherapy for stage III colorectal cancer (</offsets><xref rid="hyw140C12" ref-type="bibr"><offsets xml_i="10463" xml_f="10465" txt_i="3388" txt_f="3390">12</offsets></xref><offsets xml_i="10472" xml_f="10705" txt_i="3390" txt_f="3623">). Among them, we reached a conclusion that adjuvant FOLFOX6 would be the most appropriate as a standard treatment for lower rectal cancer with suspected LNM. FOLFOX may be effective in a neoadjuvant setting for lower rectal cancer (</offsets><xref rid="hyw140C13" ref-type="bibr"><offsets xml_i="10743" xml_f="10745" txt_i="3623" txt_f="3625">13</offsets></xref><offsets xml_i="10752" xml_f="10753" txt_i="3625" txt_f="3626">,</offsets><xref rid="hyw140C14" ref-type="bibr"><offsets xml_i="10791" xml_f="10793" txt_i="3626" txt_f="3628">14</offsets></xref><offsets xml_i="10800" xml_f="10992" txt_i="3628" txt_f="3820">). In this study, modified infusional ﬂuorouracil and folinic acid with oxaliplatin (mFOLFOX6) was adopted as an adjuvant FOLFOX regimen because it has been used in several Phase III studies (</offsets><xref rid="hyw140C15" ref-type="bibr"><offsets xml_i="11030" xml_f="11032" txt_i="3820" txt_f="3822">15</offsets></xref><offsets xml_i="11039" xml_f="11041" txt_i="3822" txt_f="3824">).</offsets></p><p><offsets xml_i="11048" xml_f="11856" txt_i="3825" txt_f="4633">We hypothesized that the preoperative introduction of chemotherapy might improve compliance with the protocol, helping to prevent the dissemination of micrometastases and improve survival compared with postoperative chemotherapy. Although we suggested 6 courses of preoperative mFOLFOX6 followed by 12 courses of postoperative mFOLFOX6 as a candidate for the experimental arm, administering a total of 18 courses of mFOLFOX6 prompted concerns about the neurotoxicity. For this reason, a total of 12 courses of mFOLFOX6, comprising 6 courses of preoperative and 6 courses of postoperative therapy, were deemed appropriate for adjuvant chemotherapy. We therefore designed the new trial JCOG1310 comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected LNM.</offsets></p></sec><sec id="hyw140s2"><title><offsets xml_i="11892" xml_f="11919" txt_i="4635" txt_f="4662">Protocol digest of JCOG1310</offsets></title><sec id="hyw140s2a"><title><offsets xml_i="11954" xml_f="11961" txt_i="4663" txt_f="4670">Purpose</offsets></title><p><offsets xml_i="11972" xml_f="12140" txt_i="4671" txt_f="4839">The purpose of this trial was to confirm the superiority of perioperative mFOLFOX6 to postoperative mFOLFOX6 in the treatment of lower rectal cancer with suspected LNM.</offsets></p></sec><sec id="hyw140s2b"><title><offsets xml_i="12177" xml_f="12190" txt_i="4841" txt_f="4854">Study setting</offsets></title><p><offsets xml_i="12201" xml_f="12293" txt_i="4855" txt_f="4947">This trial is a multi-institutional, prospective, open-label, randomized Phase II/III trial.</offsets></p></sec><sec id="hyw140s2c"><title><offsets xml_i="12330" xml_f="12339" txt_i="4949" txt_f="4958">Endpoints</offsets></title><p><offsets xml_i="12350" xml_f="13484" txt_i="4959" txt_f="6093">In Phase II part, the primary endpoint is the proportion of R0 resection, and the secondary endpoints are the proportion of operative complications and proportion of patients who complete 12 cycles of chemotherapy. In Phase III part, the primary endpoint is the overall survival which is the time from randomization to death from any cause, and the secondary endpoints are as follows: progression-free survival, local progression-free survival, proportion of patients with R0 resection, overall response rate of preoperative chemotherapy in the perioperative chemotherapy arm, pathological complete response rate in the perioperative chemotherapy arm, proportion of patients who complete 12 cycles of chemotherapy, incidence of adverse events, incidence of serious adverse events, proportion of operative complications, proportion of surgery without resection of adjuvant organs, proportion of anus-preservation and proportion of anus-preservation without stoma. Adverse events and postoperative complications were assessed in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).</offsets></p></sec><sec id="hyw140s2d"><title><offsets xml_i="13521" xml_f="13541" txt_i="6095" txt_f="6115">Eligibility criteria</offsets></title><p><offsets xml_i="13552" xml_f="13668" txt_i="6116" txt_f="6232">Rectal carcinoma is classiﬁed according to the 8th edition of Japanese Classiﬁcation of Colon and Rectal Carcinoma (</offsets><xref rid="hyw140C16" ref-type="bibr"><offsets xml_i="13706" xml_f="13708" txt_i="6232" txt_f="6234">16</offsets></xref><offsets xml_i="13715" xml_f="13759" txt_i="6234" txt_f="6278">) and the 7th edition of TNM classiﬁcation (</offsets><xref rid="hyw140C17" ref-type="bibr"><offsets xml_i="13797" xml_f="13799" txt_i="6278" txt_f="6280">17</offsets></xref><offsets xml_i="13806" xml_f="13808" txt_i="6280" txt_f="6282">).</offsets></p><sec id="hyw140s2d_1"><title><offsets xml_i="13841" xml_f="13859" txt_i="6283" txt_f="6301">Inclusion criteria</offsets></title><p><offsets xml_i="13870" xml_f="13959" txt_i="6302" txt_f="6391">Prior to enrollment in this trial, the patients must meet all of the following criteria:
</offsets><list list-type="roman-lower"><list-item><p><offsets xml_i="14003" xml_f="14066" txt_i="6391" txt_f="6454">Pathologically proven adenocarcinoma or adenosquamous carcinoma</offsets></p></list-item><list-item><p><offsets xml_i="14096" xml_f="14165" txt_i="6455" txt_f="6524">Primary tumor located in the upper rectum, lower rectum or anal canal</offsets></p></list-item><list-item><p><offsets xml_i="14195" xml_f="14281" txt_i="6525" txt_f="6611">Lower border of the tumor located between the peritoneal reflection and the anal verge</offsets></p></list-item><list-item><p><offsets xml_i="14311" xml_f="14476" txt_i="6612" txt_f="6777">cT2, cT3 and cT4 tumor on computed tomography (CT) or magnetic resonance imaging (MRI), except for a T4b tumor invading the trigone of the bladder, urethra or sacrum</offsets></p></list-item><list-item><p><offsets xml_i="14506" xml_f="14605" txt_i="6778" txt_f="6877">Lateral pelvic nodes with a short axis diameter of ≥10 mm on CT or MRI of 5-mm-thick slices (cN3) (</offsets><xref rid="hyw140C5" ref-type="bibr"><offsets xml_i="14642" xml_f="14643" txt_i="6877" txt_f="6878">5</offsets></xref><offsets xml_i="14650" xml_f="14651" txt_i="6878" txt_f="6879">,</offsets><xref rid="hyw140C18" ref-type="bibr"><offsets xml_i="14689" xml_f="14691" txt_i="6879" txt_f="6881">18</offsets></xref><offsets xml_i="14698" xml_f="14699" txt_i="6881" txt_f="6882">)</offsets></p></list-item><list-item><p><offsets xml_i="14729" xml_f="14769" txt_i="6883" txt_f="6923">No distant metastasis on CT or MRI (cM0)</offsets></p></list-item><list-item><p><offsets xml_i="14799" xml_f="14819" txt_i="6924" txt_f="6944">Aged 20–74 years old</offsets></p></list-item><list-item><p><offsets xml_i="14849" xml_f="14875" txt_i="6945" txt_f="6971">PS 0 or 1 on ECOG criteria</offsets></p></list-item><list-item><p><offsets xml_i="14905" xml_f="15037" txt_i="6972" txt_f="7104">No prior chemotherapy or treatment such as rectal resection, pelvic lymph node dissection or pelvic irradiation for any malignancies</offsets></p></list-item><list-item><p><offsets xml_i="15067" xml_f="15117" txt_i="7105" txt_f="7155">No other colorectal carcinoma, except cTis or cT1a</offsets></p></list-item><list-item><p><offsets xml_i="15147" xml_f="15255" txt_i="7156" txt_f="7264">Adequate organ function as evidenced by the following laboratory findings within 14 days prior to enrollment</offsets><list list-type="alpha-lower"><list-item><p><offsets xml_i="15299" xml_f="15327" txt_i="7264" txt_f="7292"> Neutrophil count ≥ 1500 /mm</offsets><sup><offsets xml_i="15332" xml_f="15333" txt_i="7292" txt_f="7293">3</offsets></sup></p></list-item><list-item><p><offsets xml_i="15369" xml_f="15398" txt_i="7294" txt_f="7323"> Platelet count ≥ 100 000 /mm</offsets><sup><offsets xml_i="15403" xml_f="15404" txt_i="7323" txt_f="7324">3</offsets></sup></p></list-item><list-item><p><offsets xml_i="15440" xml_f="15468" txt_i="7325" txt_f="7353"> Total bilirubin ≤ 2.0 mg/dl</offsets></p></list-item><list-item><p><offsets xml_i="15498" xml_f="15536" txt_i="7354" txt_f="7392"> Aspartate aminotransferase ≤ 100 IU/l</offsets></p></list-item><list-item><p><offsets xml_i="15566" xml_f="15602" txt_i="7393" txt_f="7429"> Alanine aminotransferase ≤ 100 IU/l</offsets></p></list-item><list-item><p><offsets xml_i="15632" xml_f="15655" txt_i="7430" txt_f="7453"> Creatinine ≤ 1.5 mg/dl</offsets></p></list-item></list></p></list-item><list-item><p><offsets xml_i="15708" xml_f="15731" txt_i="7455" txt_f="7478">Open surgery is planned</offsets></p></list-item><list-item><p><offsets xml_i="15761" xml_f="15792" txt_i="7479" txt_f="7510">Written informed consent given.</offsets></p></list-item></list></p></sec><sec id="hyw140s2d_2"><title><offsets xml_i="15854" xml_f="15872" txt_i="7513" txt_f="7531">Exclusion criteria</offsets></title><p><offsets xml_i="15883" xml_f="15976" txt_i="7532" txt_f="7625">Prior to enrollment in this trial, the patients must not meet any of the following criteria:
</offsets><list list-type="roman-lower"><list-item><p><offsets xml_i="16020" xml_f="16099" txt_i="7625" txt_f="7704">Synchronous or metachronous (within 5 years) malignancies other than carcinoma </offsets><italic><offsets xml_i="16107" xml_f="16114" txt_i="7704" txt_f="7711">in situ</offsets></italic><offsets xml_i="16123" xml_f="16144" txt_i="7711" txt_f="7732"> or mucosal carcinoma</offsets></p></list-item><list-item><p><offsets xml_i="16174" xml_f="16219" txt_i="7733" txt_f="7778">Infectious disease requiring systemic therapy</offsets></p></list-item><list-item><p><offsets xml_i="16249" xml_f="16273" txt_i="7779" txt_f="7803">Positive for HBs antigen</offsets></p></list-item><list-item><p><offsets xml_i="16303" xml_f="16325" txt_i="7804" txt_f="7826">Body temperature ≥38°C</offsets></p></list-item><list-item><p><offsets xml_i="16355" xml_f="16400" txt_i="7827" txt_f="7872">Pregnant, possibly pregnant or breast-feeding</offsets></p></list-item><list-item><p><offsets xml_i="16430" xml_f="16451" txt_i="7873" txt_f="7894">Severe mental disease</offsets></p></list-item><list-item><p><offsets xml_i="16481" xml_f="16549" txt_i="7895" txt_f="7963">Currently treated with systemic steroids or immunosuppressive agents</offsets></p></list-item><list-item><p><offsets xml_i="16579" xml_f="16653" txt_i="7964" txt_f="8038">Interstitial pneumonia, pulmonary fibrosis or severe emphysema on chest CT</offsets></p></list-item><list-item><p><offsets xml_i="16683" xml_f="16752" txt_i="8039" txt_f="8108">Uncontrollable diabetes mellitus or routine administration of insulin</offsets></p></list-item><list-item><p><offsets xml_i="16782" xml_f="16866" txt_i="8109" txt_f="8193">Unstable angina pectoris or previous myocardial infarction within the past 6 months.</offsets></p></list-item></list></p></sec></sec><sec id="hyw140s2e"><title><offsets xml_i="16932" xml_f="16945" txt_i="8197" txt_f="8210">Randomization</offsets></title><p><offsets xml_i="16956" xml_f="17372" txt_i="8211" txt_f="8627">Following conﬁrmation of the eligibility of patients using the web-based system to the JCOG Data Center, the patients will be randomized to either the postoperative chemotherapy arm or the perioperative chemotherapy arm of the study. The minimization method will be used for the randomization of patients, thereby balancing the arms of the study according to gender, tumor depth (T2-3 versus T4) and the institution.</offsets></p></sec></sec><sec id="hyw140s3"><title><offsets xml_i="17414" xml_f="17431" txt_i="8630" txt_f="8647">Treatment methods</offsets></title><sec id="hyw140s3a"><title><offsets xml_i="17466" xml_f="17473" txt_i="8648" txt_f="8655">Surgery</offsets></title><p><offsets xml_i="17484" xml_f="17593" txt_i="8656" txt_f="8765">TME with LND will be performed via open surgery for all of the patients in accordance with reported methods (</offsets><xref rid="hyw140C2" ref-type="bibr"><offsets xml_i="17630" xml_f="17631" txt_i="8765" txt_f="8766">2</offsets></xref><offsets xml_i="17638" xml_f="17639" txt_i="8766" txt_f="8767">,</offsets><xref rid="hyw140C3" ref-type="bibr"><offsets xml_i="17676" xml_f="17677" txt_i="8767" txt_f="8768">3</offsets></xref><offsets xml_i="17684" xml_f="17685" txt_i="8768" txt_f="8769">,</offsets><xref rid="hyw140C5" ref-type="bibr"><offsets xml_i="17722" xml_f="17723" txt_i="8769" txt_f="8770">5</offsets></xref><offsets xml_i="17730" xml_f="18074" txt_i="8770" txt_f="9114">). LND includes at least both sides of the common iliac nodes, proximal internal iliac nodes, distal internal iliac nodes and obturator nodes. Dissection of other lateral pelvic nodes and inguinal lymph nodes, and combined resection, such as total pelvic exenteration, of the surrounding organs or tissues are permitted to obtain R0 resection (</offsets><xref rid="hyw140C16" ref-type="bibr"><offsets xml_i="18112" xml_f="18114" txt_i="9114" txt_f="9116">16</offsets></xref><offsets xml_i="18121" xml_f="18209" txt_i="9116" txt_f="9204">). For surgical quality control and assurance, intraoperative photographs will be taken.</offsets></p></sec><sec id="hyw140s3b"><title><offsets xml_i="18246" xml_f="18276" txt_i="9206" txt_f="9236">Postoperative chemotherapy arm</offsets></title><p><offsets xml_i="18287" xml_f="18369" txt_i="9237" txt_f="9319">One course of mFOLFOX6 consists of an intravenous injection of oxaliplatin 85 mg/m</offsets><sup><offsets xml_i="18374" xml_f="18375" txt_i="9319" txt_f="9320">2</offsets></sup><offsets xml_i="18381" xml_f="18406" txt_i="9320" txt_f="9345"> with leucovorin 200 mg/m</offsets><sup><offsets xml_i="18411" xml_f="18412" txt_i="9345" txt_f="9346">2</offsets></sup><offsets xml_i="18418" xml_f="18467" txt_i="9346" txt_f="9395"> over 2 hours followed by a fluorouracil 400 mg/m</offsets><sup><offsets xml_i="18472" xml_f="18473" txt_i="9395" txt_f="9396">2</offsets></sup><offsets xml_i="18479" xml_f="18499" txt_i="9396" txt_f="9416"> bolus and 2400 mg/m</offsets><sup><offsets xml_i="18504" xml_f="18505" txt_i="9416" txt_f="9417">2</offsets></sup><offsets xml_i="18511" xml_f="18756" txt_i="9417" txt_f="9662"> continuous infusion over 46 hours. After the R0 resection, postoperative chemotherapy with mFOLFOX6 will be initiated between days 29 and 56 after surgery and repeated every 2 weeks for 12 courses for pathological Stage II or III patients only.</offsets></p></sec><sec id="hyw140s3c"><title><offsets xml_i="18793" xml_f="18823" txt_i="9664" txt_f="9694">Perioperative chemotherapy arm</offsets></title><p><offsets xml_i="18834" xml_f="19300" txt_i="9695" txt_f="10161">In the perioperative chemotherapy arm, mFOLFOX6 will be administered every 2 weeks for six courses preoperatively unless disease progression is observed on CT or MRI performed in Week 2 of Course 3. TME with LND will be performed as described above between Days 14 and 42 after the preoperative chemotherapy. Postoperative mFOLFOX6 will be initiated between Days 29 and 56 after surgery and repeated every 2 weeks for 6 courses for pathological Stage 0–III patients.</offsets></p></sec><sec id="hyw140s3d"><title><offsets xml_i="19337" xml_f="19346" txt_i="10163" txt_f="10172">Follow-up</offsets></title><p><offsets xml_i="19357" xml_f="19708" txt_i="10173" txt_f="10524">Patients will be followed-up every 3 months for the first 3 years, and subsequently every 3 months for the next 3 years. Follow-up evaluations will include a clinical examination, a blood cell count, serum chemical tests, carcinoembryonic antigen and cancer antigen (CA19-9) as tumor marker tests and thoracic/abdominal/pelvic CT at 6-month intervals.</offsets></p></sec><sec id="hyw140s3e"><title><offsets xml_i="19745" xml_f="19781" txt_i="10526" txt_f="10562">Study design and statistical methods</offsets></title><p><offsets xml_i="19792" xml_f="20302" txt_i="10563" txt_f="11070">This trial is designed to conﬁrm the superiority of the perioperative chemotherapy to the postoperative chemotherapy in terms of overall survival. In Phase II part, the primary endpoint is the proportion of R0 resection. When this proportion in the perioperative arm drops &gt;10% below that in the postoperative arm, this study will be terminated. If the expected value of the primary endpoint is 95% in both groups, 30 patients will be required in each group in order to maintain a false-negative rate of 5%.</offsets></p><p><offsets xml_i="20309" xml_f="20691" txt_i="11071" txt_f="11453">In Phase III part, we hypothesize that the 5-year overall survival of the perioperative arm will be greater than that of the postoperative arm (50%) by 10%. If the overall survival is signiﬁcantly longer with perioperative chemotherapy than postoperative, the perioperative regimen will be concluded as the new standard treatment. According to the method of Schoenfeld and Richter (</offsets><xref rid="hyw140C19" ref-type="bibr"><offsets xml_i="20729" xml_f="20731" txt_i="11453" txt_f="11455">19</offsets></xref><offsets xml_i="20738" xml_f="21065" txt_i="11455" txt_f="11782">), the required sample size will be 326 patients (163 patients per arm), with a one-sided alpha level of 5% and a power of 70% and 203 events are expected to occur during 7 years of accrual and 5 years of follow-up. Given that some patients will likely be lost to follow-up, the total target sample size is set at 330 patients.</offsets></p></sec><sec id="hyw140s3f"><title><offsets xml_i="21102" xml_f="21133" txt_i="11784" txt_f="11815">Interim analysis and monitoring</offsets></title><p><offsets xml_i="21144" xml_f="21758" txt_i="11816" txt_f="12430">We plan to conduct three interim analyses. The first interim analysis, which is a primary analysis of Phase II part, will be carried out after 60 patients have been enrolled, to determine whether this trial can proceed to Phase III status. The second interim analysis will be conducted after half of the planned number of patients has been enrolled. The third interim analysis will be conducted after the planned number of patients has been enrolled and their protocol treatment has finished. The multiplicity will be adjusted using the Lan-DeMets method with the O'Brien and Fleming-type alpha spending function (</offsets><xref rid="hyw140C20" ref-type="bibr"><offsets xml_i="21796" xml_f="21798" txt_i="12430" txt_f="12432">20</offsets></xref><offsets xml_i="21805" xml_f="21807" txt_i="12432" txt_f="12434">).</offsets></p><p><offsets xml_i="21814" xml_f="22913" txt_i="12435" txt_f="13531">The Data and Safety Monitoring Committee of the JCOG will independently review the interim analysis reports and determine if the trial should be terminated early. The trial will be terminated (i) when the proportion of R0 resection in the perioperative arm is &gt;10% lower than that in the postoperative arm in the first interim analysis, (ii) when the overall survival in the perioperative arm is inferior to that in the postoperative arm at the second or third interim analyses, (iii) when the overall survival of the perioperative arm is significantly superior to that in the postoperative arm, even with adjustment for multiplicity at the second or third interim analyses or (iv) when treatment-related deaths occur in seven patients of either arm. The JCOG Data Center and study coordinator will conduct central monitoring and issue a monitoring report every 6 months to evaluate the study progress and improve the data integrity and patient safety. For quality assurance, site visit audits will be performed by the JCOG Audit Committee (not on a study-specific basis but for the study group).</offsets></p></sec><sec id="hyw140s3g"><title><offsets xml_i="22950" xml_f="22974" txt_i="13533" txt_f="13557">Clinical trials registry</offsets></title><p><offsets xml_i="22985" xml_f="23066" txt_i="13558" txt_f="13639">This trial was registered at the UMIN Clinical Trials Registry as UMIN000017603 (</offsets><uri xlink:href="http://www.umin.ac.jp/ctr/index-j.htm"><offsets xml_i="23122" xml_f="23159" txt_i="13639" txt_f="13676">http://www.umin.ac.jp/ctr/index-j.htm</offsets></uri><offsets xml_i="23165" xml_f="23167" txt_i="13676" txt_f="13678">).</offsets></p></sec><sec id="hyw140s0026" specific-use="heading-level-1"><title><offsets xml_i="23237" xml_f="23292" txt_i="13680" txt_f="13735">Participating institutions (listed from north to south)</offsets></title><p><offsets xml_i="23303" xml_f="25168" txt_i="13736" txt_f="15601">Sapporo-Kosei General Hospital, Iwate Medical University, Miyagi Cancer Center, Yamagata Prefectural Central Hospital, Tochigi Cancer Center, Gunma Prefectural Cancer Center, National Defense Medical College, Saitama Cancer Center, Saitama Medical Center Jichi Medical University, Saitama Medical University International Medical Center, National Cancer Center Hospital East, Chiba Cancer Center, Juntendo University Urayasu Hospital, National Cancer Center Hospital, Kyorin University School of Medicine, Tokyo Medical University Hospital, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo Medical and Dental University Hospital, Toho University School of Medicine Ohashi Hospital, Kanagawa Cancer Center, Yokohama City University Medical Center, Saiseikai Yokohamashi Nanbu Hospital, Hiratsuka City Hospital, Niigata Cancer Center Hospital, Nagaoka Chuo General Hospital, Ishikawa Prefectural Central Hospital, Nagano Municipal Hospital, Gifu University School of Medicine, Shizuoka Cancer Center, Aichi Cancer Center Hospital, Fujita Health University, National Hospital Organization Kyoto Medical Center, Osaka University Faculty of Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka General Medical Center, Osaka Medical College, Sakai city hospital, Suita Municipal Hospital, Kansai Rosai Hospital, Hyogo College of Medicine, Sano Hospital, Shimane University Faculty of Medicine, Okayama Saiseikai General Hospital, Hiroshima City Hospital, Hiroshima Prefectural Hospital, Hiroshima City Asa Hospital, National Hospital Organization Shikoku Cancer Center, Kochi Health Science Center, Kurume University School of Medicine, Kumamoto University School of Medicine and Oita University Hospital. In each institution, approval by the institutional review board is obtained before starting patient accrual.</offsets></p></sec></sec><sec id="hyw140s0027" specific-use="heading-level-1"><title><offsets xml_i="25244" xml_f="25274" txt_i="15604" txt_f="15634">Conflict of interest statement</offsets></title><p><offsets xml_i="25285" xml_f="25299" txt_i="15635" txt_f="15649">None declared.</offsets></p></sec></body><back><sec id="hyw140s5"><title>Funding</title><p>
<funding-source><institution-wrap><institution>Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source> (AMED, <award-id>15ck0106156h0001</award-id>); <funding-source><institution-wrap><institution>National Cancer Center Research and Development Fund</institution></institution-wrap></funding-source> (<award-id>26-A-4</award-id>) (partial support).</p></sec><ref-list><title>References</title><ref id="hyw140C1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuda</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Matsuda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shibata</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project</article-title>. <source>Jpn J Clinl Oncol</source>
<year>2013</year>;<volume>44</volume>:<fpage>388</fpage>–<lpage>96</lpage>.</mixed-citation></ref><ref id="hyw140C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacFarlane</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Ryall</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Heald</surname><given-names>RJ</given-names></name></person-group>
<article-title>Mesorectal excision for rectal cancer</article-title>. <source>Lancet</source>
<year>1993</year>;<volume>341</volume>:<fpage>457</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">8094488</pub-id></mixed-citation></ref><ref id="hyw140C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moriya</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sugihara</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Akasu</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Nerve-sparing surgery with lateral node dissection for advanced lower rectal cancer</article-title>. <source>Eur J Cancer</source>
<year>1995</year>;<volume>31A</volume>:<fpage>1229</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">7577028</pub-id></mixed-citation></ref><ref id="hyw140C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusters</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Beets</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>van de Velde</surname><given-names>CJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence</article-title>. <source>Ann Surg</source>
<year>2009</year>;<volume>249</volume>:<fpage>229</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">19212175</pub-id></mixed-citation></ref><ref id="hyw140C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Akasu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mizusawa</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial</article-title>. <source>Lancet Oncol</source>
<year>2012</year>;<volume>13</volume>:<fpage>616</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">22591948</pub-id></mixed-citation></ref><ref id="hyw140C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akiyoshi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Miyata</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease</article-title>. <source>Ann Surg</source>
<year>2012</year>;<volume>255</volume>:<fpage>1129</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">22549752</pub-id></mixed-citation></ref><ref id="hyw140C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gijn</surname><given-names>WV</given-names></name>, <name name-style="western"><surname>Marijnen</surname><given-names>CAM</given-names></name>, <name name-style="western"><surname>Nagtegaal</surname><given-names>ID</given-names></name>, <etal>et al</etal></person-group>
<article-title>Preoperative radiotherapy combined with total mesorectal excision fore resectable rectal cancer</article-title>. <source>Lancet Oncol</source>
<year>2011</year>;<volume>15</volume>:<fpage>575</fpage>–<lpage>82</lpage>.</mixed-citation></ref><ref id="hyw140C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Jeopng</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>DH</given-names></name>, <etal>et al</etal></person-group>
<article-title>Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection</article-title>. <source><italic>Ann Surg Onc</italic>ol</source>
<year>2008</year>;<volume>15</volume>:<fpage>729</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">18057989</pub-id></mixed-citation></ref><ref id="hyw140C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>SH</given-names></name><name name-style="western"><surname>Harling</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kirkeby</surname><given-names>LT</given-names></name>, <etal>et al</etal></person-group>
<article-title>Postoperative adjuvant chemotherapy in rectal cancer operated for cure</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2012</year>;<volume>3</volume>:<fpage>CD004078</fpage>
<comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/14651858.CD004078.pub2">doi:10.1002/14651858.CD004078.pub2</ext-link></comment>.</mixed-citation></ref><ref id="hyw140C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamaguchi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shirao</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Moriya</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC)</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2011</year>;<volume>67</volume>:<fpage>587</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">20490797</pub-id></mixed-citation></ref><ref id="hyw140C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>André</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Boni</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Navarro</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial</article-title>. <source>J Clin Oncol</source>
<year>2009</year>;<volume>27</volume>:<fpage>3109</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">19451431</pub-id></mixed-citation></ref><ref id="hyw140C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Itabashi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shimada</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer</article-title>. <source>Int J Clin Oncol</source>
<year>2015</year>;<volume>20</volume>:<fpage>207</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">25782566</pub-id></mixed-citation></ref><ref id="hyw140C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cercek</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Weiser</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>KA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation</article-title>. <source>J Clin Oncol</source>
<year>2010</year>;<volume>28</volume>:<fpage>15s</fpage> (suppl; abstr 3649).</mixed-citation></ref><ref id="hyw140C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schrag</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Weiser</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>KA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial</article-title>. <source>J Clin Oncol</source>
<year>2014</year>;<volume>32</volume>:<fpage>513</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">24419115</pub-id></mixed-citation></ref><ref id="hyw140C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allegra</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Yothers</surname><given-names>G</given-names></name>, <name name-style="western"><surname>O'Connell</surname><given-names>MJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08</article-title>. <source>J Clin Oncol</source>
<year>2011</year>;<volume>29</volume>:<fpage>11</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">20940184</pub-id></mixed-citation></ref><ref id="hyw140C16"><label>16</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Japanese Society of Cancer of the Colon and Rectum</collab></person-group>
<source>General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum, and Anus</source>. <edition>8th edn</edition>
<publisher-loc>Tokyo</publisher-loc>: <publisher-name>Kanehara</publisher-name>, <year>2013</year> (in Japanese).</mixed-citation></ref><ref id="hyw140C17"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sobin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wittekind</surname><given-names>C</given-names></name></person-group>
<source>TNM Classiﬁcation of Malignant Tumours</source>. <edition>7th edn</edition>
<publisher-loc>New York</publisher-loc>: <publisher-name>Wiley-Liss</publisher-name>, <year>2009</year>.</mixed-citation></ref><ref id="hyw140C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akasu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Iinuma</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Takawa</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Accuracy of high-resolution magnetic resonance imaging in preoperative staging of rectal cancer</article-title>. <source>Ann Surg Oncol</source>
<year>2009</year>;<volume>16</volume>:<fpage>2787</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">19618244</pub-id></mixed-citation></ref><ref id="hyw140C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoenfeld</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Richter</surname><given-names>JR</given-names></name></person-group>
<article-title>Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint</article-title>. <source>Biometric</source>
<year>1982</year>;<volume>38</volume>:<fpage>163</fpage>–<lpage>70</lpage>.</mixed-citation></ref><ref id="hyw140C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>KKG</given-names></name>, <name name-style="western"><surname>DeMets</surname><given-names>DL</given-names></name></person-group>
<article-title>Discrete sequential boundaries for clinical trials</article-title>. <source>Biometrika</source>
<year>1983</year>;<volume>70</volume>:<fpage>659</fpage>–<lpage>63</lpage>.</mixed-citation></ref></ref-list></back></article>